Open an account

Faeth Therapeutics

FTH · NASDAQ

$20.79+$1.35 (+6.94%)TodayMarket closed ·
Prev close $19.44

About FTH

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Austin, Texas and currently employs 29 full-time employees. The company went IPO on 2021-02-04. The firm's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.

Employees
29
Headquarters
Austin, Texas
Listed
Feb 4, 2021
Sector
Health Care
Industry
Biotechnology
Website
senseibio.com

FTH key statistics

Market cap
537.22M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
363.79K
Volume
806.00K
Open price
$19.04
High today
$21.72
Low today
$18.49
52 Week high
$42.14
52 Week low
$7.45

Faeth Therapeutics (FTH) at a glance

As of Oct 20, 2026, Faeth Therapeutics (FTH) shares are priced at $20.79, giving the company a market cap of 537.22M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $18.49 and $21.72. The current price is 12.4% above the day's low and 4.3% below its high.

Volume so far is 806.00K shares, above the average of 363.79K shares a day.

Over the past year Faeth Therapeutics has ranged from $7.45 to $42.14, and now sits 38% of the way up that range.

Faeth Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$2.84 per share against an estimate of -$3.08.

The average analyst price target is $57.80, 178.0% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 12 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 13 analystsAvg $57.80
Low
$46.46
Now
$20.79
High
$73.50

FTH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 16.5% on average.

  1. Q3 FY24: reported -$5.80 per share against an estimate of -$6.31
  2. Q4 FY24: reported -$6.20 per share against an estimate of -$5.59
  3. Q1 FY25: reported -$5.40 per share against an estimate of -$4.51
  4. Q2 FY25: reported -$3.91 per share against an estimate of -$5.66
  5. Q3 FY25: reported -$3.62 per share against an estimate of -$4.15
  6. Q4 FY25: reported -$3.74 per share against an estimate of -$4.86
  7. Q1 FY26: reported -$28.79 per share against an estimate of -$0.6262
  8. Q2 FY26: reported -$2.84 per share against an estimate of -$3.08

FTH news

  • Press releaseBusiness Wire

    Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026

  • Press releaseBusiness Wire

    Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors

  • Press releaseBusiness Wire

    Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026

  • Press releaseBusiness Wire

    Faeth Therapeutics to Participate in Upcoming September Investor Conferences

  • Press releaseBusiness Wire

    Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

  • Press releaseBusiness Wire

    Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

  • Press releaseBusiness Wire

    Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Similar companies

Companies in the same industry as Faeth Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.